Introduction: 72
Premature neonates born before 32 weeks of gestation or with a birth weight <1500 74 grams are predisposed to necrotizing enterocolitis (NEC), an idiopathic, inflammatory bowel 75 necrosis characterized by pneumatosis intestinalis (accumulation of gaseous products of 76 bacterial fermentation within the bowel wall), inflammation, and tissue necrosis.
1-2 Existing data 77 indicate that bacterial flora normally present in the gut lumen, not specific bacterial pathogens, 78 play a major role in the pathogenesis of NEC.
1-2 The pathophysiological importance of bacteria 79 in NEC is underscored by the frequent detection of bacteria and pneumatosis in intestinal 80 tissue, occurrence of NEC only after postnatal bacterial colonization and never in the sterile 81 intrauterine microenvironment prior to birth, inability to induce NEC-like lesions in germ-free 82 experimental animals, and by observations that enteral antibiotics may reduce the incidence of 83 NEC in preterm infants.
2-3 Based on current evidence, NEC is believed to occur when mucosal 84 injury or altered permeability in the preterm intestine permits the translocation of luminal 85 bacteria across the epithelial barrier, which, in turn, triggers a severe inflammatory response. 2, 4 86 87 Gut mucosal injury and bacterial translocation are frequent events in critically-ill patients 88 of all ages, but unlike in premature infants, these invading bacteria do not evoke a NEC-like 89 inflammatory response in the mature intestinal mucosa. Bacteria that breach the gut epithelial 90 barrier are normally eliminated by resident macrophages in the lamina propria, the first 91 phagocytic cells of the innate immune system to encounter these microorganisms. [5] [6] Unlike 92 macrophages in other organ systems that release cytokines/chemokines upon phagocytosis of 93 bacteria to stimulate a local inflammatory response, intestinal macrophages are profoundly 94 suppressed for cytokine production. 6 This unique dichotomy of phagocytic versus inflammatory 95 properties in intestinal macrophages plays an important role in maintaining the normal absence 96 of inflammation in the gut mucosa (despite close proximity to immunostimulatory bacteria), as 97 illustrated by spontaneous onset of enterocolitis in genetically-modified mice with defects in 98 differentiation of intestinal macrophages. [6] [7] [8] [9] In this context, we hypothesized that the risk of NEC 99 in the premature intestine is related to the state of differentiation of intestinal macrophages. We 100 postulated that the non-inflammatory differentiation of intestinal macrophages is a function of 101 gestational maturation and is therefore, incomplete in the preterm intestine, increasing the risk 102 of a severe mucosal inflammatory response to bacterial products. In this study, we investigate 103 maturational changes in gut macrophage differentiation in the context of NEC using a variety of 104 in-vitro and in-vivo models. 105
propria, and the remaining tissue was incubated overnight in serum-free RPMI. The exfoliated 143 epithelial cells were incubated overnight in a separate plate to prepare epithelial-conditioned 144 media (E-CMs). In some experiments, we used intact tissue (with epithelium) to prepare the T-145 CMs. A detailed protocol is included in the online supplement. 146
147
Treatment of monocyte-derived macrophages with T-CMs: Blood monocytes from healthy 148 adult volunteers were isolated by Ficoll-Hypaque centrifugation and immunoselection with CD14 149 microbeads (Miltenyi).
10 Monocyte-derived macrophages (20,000/well) were incubated in 96-150 well plates with T-CM (250, 500, and 1000 µg total protein/mL) x 2-24 hrs and then stimulated 151 with 500 ng/mL E. coli LPS (pre-determined optimum; Sigma) for up to 18 hrs. 152
153
Measurement of inflammatory cytokines: TNF-α (human and murine), IL-6, IL-1β, and IL-8 154
were measured by commercially-available ELISA kits (R&D, Minneapolis, MN). 155
156
Neutrophil chemotaxis: Culture supernatants from monocyte-derived macrophages were tested 157 for neutrophil chemotactic activity using our fluorescence-based protocol 17 described in the online 158 supplement. 159 160 NF-κB activation: Macrophages were treated with T-CMs and LPS as above. NF-κB p65 161 phosphorylation was measured by ELISA (SuperArray Biosciences). 162 163 TGF-bioactivity: TGF-β bioactivity was measured by a quantitative luciferase assay; T-CMs 164 were added for 16 hrs to mink lung epithelial cells transfected with a luciferase plasmid 165 containing the TGF-β-responsive promoter of the platelet activator inhibitor-1 (PAI-1) gene; 18 Smad2/3 phosphorylation (ser423, ser425) was measured by western blots using polyclonal 167 antibodies against total and phosphorylated smad 2 (Santa Cruz) and appropriate secondary 168 reagents.
19 TGF-β activity was neutralized in vitro by addition of excess (15 or 50 µg/mL) 169 neutralizing anti-human TGF-β antibody. 170
171
Assays for TGF-β isoforms: Total and active TGF-β 1 , TGF-β 2 , and TGF-β 3 were measured by 172 ELISA (R&D). T-CMs containing only one unique TGF-β isoform were derived from 20-24 wk T-173 CMs (n=3) by removing two of the three TGF-β isoforms by immunoprecipitation;
19 the 174 presence/absence of TGF-β isoforms was confirmed by ELISA. Macrophages were treated with 175 parent or derivative T-CM prior to LPS stimulation. In some experiments, we treated 176 macrophages with 15.6-2000 pg/mL recombinant human TGF-β 1 , TGF-β 2 , and TGF-β 3 (R&D) 177 instead of T-CMs before stimulation with LPS. 178
179
Mice: DNIIR mice 20 were treated with zinc sulfate (50 µg/gm/day subcutaneous; pre-determined 180 optimum dose) for up to 7 days. Identification of DNIIR mice and measurement of DNIIR 181 mRNA 20 is described in the online supplement. To confirm the loss of TGF-β-mediated signaling 182 upon zinc supplementation, we administered recombinant TGF-β 2 (100 ng, intra-peritoneal) in 183 DNIIR mice (after 0, 3, and 7 days of zinc supplementation) and measured smad 184 phosphorylation in intestinal tissue after 1 hour. 185 whether enterally-administered TGF-β 2 protected against mucosal injury, we treated some mice 192 with 100 ng recombinant TGF-β 2 2 hours prior to PAF and LPS administration. The protective 193 effect of TGF-β 2 were confirmed in a second experimental model of NEC 24 where 10-day-old 194 mouse pups were separated from the dam, provided formula feedings every 3 hours and 195 exposed to hypoxia (5% oxygen for 2 min) twice daily prior to feedings. mouse intestine as a model system. 8 In support of our immunohistochemical data from the 232 human intestine, murine intestinal macrophages from embryonic day 15 (E15) and E18 fetuses, 233 but not from newborn pups or adults, produced TNF-α following LPS stimulation in vitro (Fig.  234   1B) . 235
236
We have shown previously that intestinal macrophages are derived from 'pro-237 inflammatory' blood monocytes, which differentiate under the influence of the extracellular 238 matrix (ECM) in the lamina propria to acquire a 'non-inflammatory' profile. 5, 10 To explain the 239 intact inflammatory responses of fetal intestinal macrophages, we hypothesized that tissue 240 factor(s) that suppress the inflammatory responses of macrophage precursors in the intestine 241 are expressed as a function of gestational maturation, and are therefore, deficient in the fetus. 242
To test this possibility, we treated E15 intestinal macrophages (exposed in vivo to an immature 243 matrix) and 'supplied' the differentiating factor(s) missing from the fetal intestine by adding 244 media conditioned with ex planted adult mouse jejunum. In support of our hypothesis, adult T-245
CMs suppressed fetal intestinal macrophages for LPS-induced TNF-α production (inset). Consistent with our hypothesis, we found that the suppressive effect of fetal T-CMs on LPS-255 induced macrophages cytokine production increased with gestational age but remained 256 significantly less than that of adult T-CM ( Fig. 2A ; supporting data from a real-time PCR array 257 shown in Supplementary fig. 1 ). T-CM suppression of macrophage cytokine production 258 followed a similar pattern when macrophages were stimulated with heat-killed Listeria 259 monocytogenes (to stimulate toll-like receptor-2) instead of LPS (not depicted). 260
261
The maturational increase in T-CM suppression of macrophage cytokine production was 262 not affected by variations in the protocol for T-CM preparation, such as the presence or absence 263 of IECs on ex planted intestinal tissue. A similar (albeit weaker) maturational pattern wasdetected when culture supernatants from exfoliated IECs were added to macrophage cultures 265 instead of T-CMs (Supplementary fig. 2 ). Finally, as T-CMs from premature and full-term 266 neonatal tissue were not available, we used tissue lysates of frozen intestinal tissue samples 267 from 20-24 wk fetuses, term neonates, and adults in some experiments. These lysates were 268 less efficacious than T-CMs but showed a similar maturational increase in the suppression of 269
LPS-induced TNF-α production (not depicted). 270 271

Media conditioned with human intestinal tissue induce LPS-tolerance in human 272
peripheral blood monocyte-derived macrophages by providing TGF-β: To understand the 273 inflammatory downregulation of intestinal macrophages, we evaluated TGF-β-, IL-10-, and 274 programmed death-1-ligand 1 (PD1L1)-mediated effects as possible mechanisms.
9 TGF-β was 275 the most plausible mediator of these effects because the inflammatory downregulation of 276 intestinal macrophages can be reproduced by exposing macrophages to ECM products present 277 in T-CMs, and preformed TGF-β, but not IL-10 and PD1L1, is stored in intestinal ECM.
278
Consistent with the maturational increase in T-CM suppression of macrophage cytokine 279 production, we detected increasing TGF-β bioactivity in these T-CMs (Fig. 3A) . Similarly, T-CM 280 treatment of macrophages induced the phosphorylation of smad2 (a signaling event specifically 281 associated with TGF-β), which became progressively more robust with increasing gestational 282 age of the intestinal tissue sample (Fig. 3B) . The role of TGF-β in T-CM suppression of 283 macrophage cytokine production was confirmed by the reversal of T-CM effects upon 284 neutralization of TGF-β (Fig. 3C) . 285
286
Media conditioned with human intestinal tissue suppress cytokine production in human 287 monocyte-derived macrophages primarily via the TGF-β 2 isoform: The expression of TGF-288 β 2 , but not TGF-β 1 or TGF-β 3 , increased in intestinal tissue with maturation ( Fig. 4A-C) . Toascertain the relative contribution of the three TGF-β isoforms to the anti-inflammatory effects of 290 T-CMs, we removed two of three isoforms in different aliquots of T-CMs by immunoprecipitation. 291
T-CM derivatives containing TGF-β 2 were most effective in suppressing LPS-induced cytokine 292 production ( Fig. 4D) . TGF-β 1 had a smaller effect, whereas TGF-β 3 did not affect macrophage 293 cytokine production. These effects were blocked by neutralizing isoform-specific antibodies 294 (R&D, not depicted). In support of these data, we found that recombinant human TGF-β 2 was 295 more potent than recombinant TGF-β 1 or recombinant TGF-β 3 in suppressing macrophage 296 cytokine production (inset). 297 298
TGF-β 2 expression is decreased in intestinal tissues samples resected from patients with 299
NEC: Based on our findings, we argued that macrophages in preterm intestine, which are yet to 300 undergo inflammatory downregulation, should predispose all premature infants to inflammatory 301 mucosal injury. In this context, the actual 5-15% incidence of NEC in premature infants 302 appeared to be surprisingly low. To investigate whether clinically-evident NEC occurs in infants 303 with the lowest levels of TGF-β 2 expression, we compared tissue expression of TGF-β 2 in NEC 304 (n=8; mean gestational age ± standard error = 28±1.5 wks) versus intestinal conditions other 305 than NEC (n=5; 29.1±2 wks) and normal midgestation fetal intestine (n=6; 22±0.4 wks). TGF-β 2 306 expression and TGF-β bioactivity were lower in NEC than in the controls (Fig. 4) . The 307 concentrations of TGF-β 1 were also lower in NEC (not depicted), while TGF-β 3 was expressed 308 near the lower limit of detection. 309 310 TGF-β protects mouse pups against NEC-like intestinal injury: We next used a murine 311 model to investigate whether decreased TGF-β-mediated signaling could worsen inflammatory 312 mucosal injury. Although TGF- 2 was the most potent of the three TGF-β isoforms inhigh concentrations (Fig. 4D) . In the intestine, TGF- is normally stored in a bound-form in the 315 lamina propria, where these peptides are anchored to ECM proteins. 5 Depending on the 316 physical proximity to a differentiating macrophage, these matrix stores of TGF- could 317 theoretically provide biologically-relevant local concentrations of TGF- 1 and/or TGF- 3 in the 318 immediate microenvironment of the macrophage. Based on these considerations, we could not 319 exclude the possibility of some redundancy in the anti-inflammatory effects of TGF- isoforms 320 and therefore, opted against the use of isoform-specific deletion/neutralization models. We used 321 a transgenic mouse that can be induced to lose TGF-β receptor II (TGF-β RII) expression and 322 consequently, all TGF-β-mediated signaling. In these DNIIR mice, 20 which express a kinase-323 defective TGF-β RII transgene upon zinc supplementation, we were able to induce a partial 324 deficiency of TGF-β effects after 3 days of zinc supplementation and a complete abrogation of 325 all TGF-β signaling after 7 days (supplementary Fig. 3 ). To determine whether TGF-β protects 326 the neonatal intestine against inflammatory injury, we induced gut mucosal injury by 327 intraperitoneal administered PAF and LPS in wild-type, 3-day-zinc DNIIR, and 7-day-zinc DNIIR 328 mice (n=18 per group). The severity of intestinal injury worsened with increasing loss of TGF-β 329 effects in the intestine (Fig. 6A) . 330
331
We next investigated whether enterally-administered recombinant TGF-β 2 could protect 332 against inflammatory mucosal injury in mouse pups. The enteral route was chosen because (1) 333 TGF-β 2 is normally expressed in human milk in high concentrations [26] [27] and (2) TGF-β receptors 334 (TGF-β RI, TGF-β RII, and TGF-β RIII) are widely-expressed in human fetal as well as murine 335 intestine (Supplementary fig. 4 ). Administration of recombinant TGF-β 2 (100 ng; dose 336 calculated to provide 10 times the amount of TGF-β 2 received by a rodent pup in one day) 28 by 337 gavage 2 hours prior to PAF and LPS administration protected these pups against mucosal 338 injury (Fig. 6B) . We then confirmed the protective effects of TGF-β 2 in another experimentalmodel of NEC, where formula-fed 10-day-old mouse pups exposed to hypoxia and hypothermia 340 develop intestinal injury. Similar to the results in our PAF-LPS model, daily administration of 341 TGF-β 2 (100 ng; one single dose in morning for 4 days) was protective against mucosal injury in 342 this model (Fig. 6C) . In addition to the reduced severity of intestinal injury, we also noted a 343 reduction in the frequency of injury (9 control implications. In contrast to the 'non-inflammatory' functional profile of intestinal macrophages 366 seen in the mature host, we show that macrophages in the preterm intestine can respond to 367 bacterial products to produce a robust inflammatory response. In the normal fetus, intestinal 368 macrophages undergo progressive inflammatory downregulation and resemble macrophages in 369 the adult intestine by term gestation. However, in the event of a midgestation delivery, when the 370 inflammatory downregulation of the resident macrophages is still incomplete, 'premature' 371 bacterial colonization of the intestinal mucosa may predispose these infants to inflammatory 372 mucosal injury as seen during NEC (Fig. 7) . 373
374
The progressive suppression of inflammatory responses of intestinal macrophages we 375 observed during gestational development mirrors a similar maturational reduction in the 376 expression of inflammatory cytokines in the gut epithelium, indicating that these changes may 377 be a part of a larger, more generalized change in the inflammatory milieu in the intestine. We report for the first time that TGF-β 2 expression and TGF-β bioactivity is decreased in 399 NEC. TGF-β 2 expression was decreased in NEC to levels even lower than the premature/fetal 400 intestine, suggesting that genetic/epigenetic variability in TGF-β 2 expression may increase the 401 risk of NEC in a premature neonate. The low levels of TGF-β we observed in NEC are unique to 402 NEC and are not due to consumption during mucosal inflammation; TGF-β expression is 403 increased in mucosal inflammatory states such as ulcerative colitis and Crohn's disease. Several studies have now shown that cytokines and growth factors present in amniotic 410 fluid and human milk can survive digestion in the stomach and the proximal small intestine bybinding to cognate receptors on the epithelium, due to deficiency of digestive enzymes during 412 early neonatal period, or because of an intrinsic resistance to gastric and enteral proteases in 413 many cytokines due to the presence of specific structural motifs that render these peptides 414 resistant to digestion. 27 The neonatal intestinal epithelium can absorb intact proteins and other 415 macromolecules, indicating that enterally-administered cytokines such as TGF-β 2 may be 416 bioavailable in the mucosa.
27 TGF-β 2 is expressed in high concentrations in amniotic fluid and 417 human milk and is therefore, normally ingested by the fetus and newborn infant in large 418 amounts. [26] [27] In contrast, the absence of TGF-β 2 in infant formula calls for speculation that the 419 protective effect of breast milk against NEC (as compared to formula) may be, at least partially, 420 due to TGF-β 2 (Fig. 7) . Since recombinant TGF-β 2 can be easily synthesized in large amounts, 421 our findings justify aggressive evaluation of the safety and efficacy of enterally-administered 422 TGF-β 2 as a prophylactic strategy against NEC. 
